参考文献/References:
[1]Kim YG,Shim J,Oh SK,et al. Risk factors for ischemic stroke in atrial fibrillation patients undergoing radiofrequency catheter ablation[J]. Sci Rep,2019,9(1):7051.
[2]Rong B,Han W,Lin M,et al. Thromboembolic risk of cessation of oral anticoagulation post catheter ablation in patients with and without atrial fibrillation recurrence[J]. Am J Cardiol,2020,137:55-62.
[3]Yaghi S,Moon YP,Mora-McLaughlin C,et al. Left atrial enlargement and stroke recurrence:the Northern Manhattan Stroke Study[J]. Stroke,2015,46(6):1488-1493.
[4]Cetin EHO,Ozbay MB,Cetin MS,et al. A new risk model for the evaluation of the thromboembolic milieu in patients with atrial fibrillation:the PALSE score[J]. Kardiol Pol,2020,78(7-8):732-740.
[5]Lang RM,Badano LP,Mor-Avi V,et al. Recommendations for cardiac chamber quantification by echocardiography in adults:an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging,2015,16(3):233-270.
[6]Osranek M,Bursi F,Bailey KR,et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation:three-decade follow-up[J]. Eur Heart J,2005,26(23):2556-2561.
[7]Shen MJ,Arora R,Jalife J. Atrial myopathy[J]. JACC Basic Transl Sci,2019,4(5):640-654.
[8]Leung M,van Rosendael PJ,Abou R,et al. Left atrial function to identify patients with atrial fibrillation at high risk of stroke:new insights from a large registry[J]. Eur Heart J,2018,39(16):1416-1425.
[9]Kusunose K,Takahashi H,Nishio S,et al. Predictive value of left atrial function for latent paroxysmal atrial fibrillation as the cause of embolic stroke of undetermined source[J]. J Cardiol,2021,78(5):355-361
[10]Park JH,Joung B,Son NH,et al. The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation[J]. Europace,2011,13(11):1541-1549.
[11]Hohendanner F,Romero I,Blaschke F,et al. Extent and magnitude of low-voltage areas assessed by ultra-high-density electroanatomical mapping correlate with left atrial function[J]. Int J Cardiol,2018,272:108-112.
[12]Wang B,Chu H,He B,et al. Association of left atrial appendage voltage with ischemic stroke in patients with atrial fibrillation[J]. Acta Cardiol Sin,2019,35(6):592-599.
[13]Ribo T,Jianzeng D,Xiaohui L,et al. Impact of CHA2DS2 VASc score on substrate for persistent atrial fibrillation and outcome post catheter ablation of atrial fibrillation[J]. Zhonghua Xin Xue Guan Bing Za Zhi,2015,43(8):695-699.
[14]Hijazi Z,Oldgren J,Andersson U,et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation:a Randomized Evaluation of Long-term Anticoagulation Therapy(RE-LY) substudy[J]. Circulation,2012,125(13):1605-1616.
[15]Hijazi Z,Siegbahn A,Andersson U,et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation:insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation(ARISTOTLE) trial[J]. Circulation,2014,129(6):625-634.
[16]Providência R,Paiva L,Faustino A,et al. Cardiac troponin I:prothrombotic risk marker in non-valvular atrial fibrillation[J]. Int J Cardiol,2013,167(3):877-882.
[17]Hijazi Z,Lindb?ck J,Alexander JH,et al. The ABC(age,biomarkers,clinical history) stroke risk score:a biomarker-based risk score for predicting stroke in atrial fibrillation[J]. Eur Heart J,2016,37(20):1582-1590.
[18]Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[19]Hamatani Y,Iguchi M,Ueno K,et al. Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure[J]. Heart,2021,107(9):705-712.
[20]Hijazi Z,Wallentin L,Siegbahn A,et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation:insights from the ARISTOTLE Trial(Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)[J]. J Am Coll Cardiol,2013,61(22):2274-2284.
[21]Hijazi Z,Oldgren J,Andersson U,et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation:a RE-LY substudy[J]. Heart,2014,100(15):1193-1200.
[22]Zhang M,Wang Y,Wei J,et al. BNP combined with echocardiographic parameters to predict the risk of cardioembolic stroke[J]. J Clin Neurosci,2021,88:213-218.
[23]Conway DSG,Buggins P,Hughes E,et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation[J]. J Am Coll Cardiol,2004,43(11):2075-2082.
[24]Aulin J,Hijazi Z,Siegbahn A,et al. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation:insights from ARISTOTLE and RE-LY trials[J]. J Thromb Haemost,2020,18(9):2287-2295.
[25]Saliba W,Barnett-Griness O,Elias M,et al. Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation:a cohort study[J]. J Thromb Haemost,2015,13(11):1971-1979.
[26]Zuo K,Yang X. Decreased platelet-to-lymphocyte ratio as predictor of thrombogenesis in nonvalvular atrial fibrillation[J]. Herz,2020,45(7):684-688.
[27]Rivera-Caravaca JM,Marín F,Vilchez JA,et al. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores[J]. Stroke,2019,50(6):1372-1379.
[28]Bayés de Luna A,Platonov P,Cosio FG,et al. Interatrial blocks. A separate entity from left atrial enlargement:a consensus report[J]. J Electrocardiol,2012,45(5):445-451.
[29]Prasitlumkum N,Cheungpasitporn W,Mekritthikrai R,et al. Interatrial block and its association with an increased risk of ischemic stroke:a systematic review and meta-analysis[J]. J Electrocardiol,2020,61:92-98.
[30]Martínez-Sellés M,Elosua R,Ibarrola M,et al. Advanced interatrial block and P-wave duration are associated with atrial fibrillation and stroke in older adults with heart disease:the BAYES registry[J]. Europace,2020,22(7):1001-1008.
[31]He J,Tse G,Korantzopoulos P,et al. P-wave indices and risk of ischemic stroke:a systematic review and meta-analysis[J]. Stroke,2017,48(8):2066-2072.
[32]McConkey N,Malamas P,Norby FL,et al. Abnormal P-wave terminal force in lead V1 is associated with low left atrial appendage ejection velocity[J]. J Electrocardiol,2021,67:142-147.
[33]Dogan A,Kahraman H,Ozturk M,et al. P wave dispersion and left atrial appendage function for predicting recurrence after conversion of atrial fibrillation and relation of P wave dispersion to appendage function[J]. Echocardiography,2004,21(6):523-530.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(5):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[12]白金龙 李洪仕 蔡衡.非瓣膜性心房颤动导管消融术后抗凝策略的研究进展[J].心血管病学进展,2021,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.201.01.000]
[13]魏言昭 唐艳红.心房颤动患者的脑卒中风险评估及危险因素的最新进展[J].心血管病学进展,2021,(11):1032.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WEI YanzhaoTANG Yanhong.Stroke Risk Evaluation and Risk Factors in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(5):1032.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[14]加依娜·加尔肯 汤宝鹏 周贤惠 李耀东 芦颜美.非瓣膜性心房颤动患者“一站式”手术策略的有效性和安全性:单中心经验[J].心血管病学进展,2022,(12):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
Jiayina Jiaerken,TANG Baopeng,ZHOU Xianhui,et al.Effectiveness and Safety of "One-Step" Procedure in Patients with Non-Valvular Atrial Fibrillation:A Single Center Experience?/html>[J].Advances in Cardiovascular Diseases,2022,(5):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
[15]陈建福 陈灿.血压目标范围内时间与心血管疾病关系的研究进展[J].心血管病学进展,2024,(7):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]
CHEN Jianfu,CHEN Can.The Relationship Between Time in Target Range and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(5):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]